Gene and cell therapy has made a great breakthrough in recent years, however, the industry is facing challenges in developing stable and scalable manufacturing processes for viral vectors. GenScript ProBio is dedicated to develop platforms to produce viral vectors, and currently, it has robust viral vector manufacturing processes using both adherent culture and suspension culture. GenScript ProBio has vast experience in assisting several customers to submit IND to FDA and NMPA, and supporting manufacturing for clinical phase use.

In this webinar, you will learn:
1. Challenges in process development of viral vector
2. Viral vector manufacturing using adherent and suspension platforms
3. GenScript ProBio track record

свернуть